<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
72309-004-01
</NDCCode>
<PackageDescription>
154 VIAL, GLASS in 1 BOX (72309-004-01) / 210 mg in 1 VIAL, GLASS
</PackageDescription>
<NDC11Code>
72309-0004-01
</NDC11Code>
<ProductNDC>
72309-004
</ProductNDC>
<ProductTypeName>
DRUG FOR FURTHER PROCESSING
</ProductTypeName>
<ProprietaryName/>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Olanzapine Pamoate
</NonProprietaryName>
<DosageFormName>
POWDER, FOR SUSPENSION
</DosageFormName>
<RouteName/>
<StartMarketingDate>
20250122
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
DRUG FOR FURTHER PROCESSING
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
Evonik Corporation
</LabelerName>
<SubstanceName>
OLANZAPINE PAMOATE
</SubstanceName>
<StrengthNumber>
1
</StrengthNumber>
<StrengthUnit>
mg/mg
</StrengthUnit>
<Pharm_Classes/>
<DEASchedule/>
<Status>
Unfinished
</Status>
<LastUpdate>
2025-06-24
</LastUpdate>
<PackageNdcExcludeFlag/>
<ProductNdcExcludeFlag/>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
22-JAN-25
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>